These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12604695)

  • 41. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions.
    Broening HW; Morford LL; Vorhees CV
    Synapse; 2005 May; 56(2):84-93. PubMed ID: 15714503
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat.
    Schaefer TL; Ehrman LA; Gudelsky GA; Vorhees CV; Williams MT
    J Neurochem; 2006 Sep; 98(5):1369-78. PubMed ID: 16923155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.
    Hanson JE; Birdsall E; Seferian KS; Crosby MA; Keefe KA; Gibb JW; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2009 Apr; 607(1-3):68-73. PubMed ID: 19326567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression.
    Brown JM; Gouty S; Iyer V; Rosenberger J; Cox BM
    J Neurochem; 2006 Jul; 98(2):495-505. PubMed ID: 16749908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.
    Riddle EL; Topham MK; Haycock JW; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2002 Aug; 449(1-2):71-4. PubMed ID: 12163108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
    Frey K; Kilbourn M; Robinson T
    Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurotoxic methamphetamine regimens produce long-lasting changes in striatal G-proteins.
    Boikess SR; O'Dell SJ; Marshall JF
    Synapse; 2010 Nov; 64(11):839-44. PubMed ID: 20336628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
    McFadden LM; Hadlock GC; Allen SC; Vieira-Brock PL; Stout KA; Ellis JD; Hoonakker AJ; Andrenyak DM; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2012 Feb; 340(2):295-303. PubMed ID: 22034657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized rats.
    Shuto T; Seeman P; Kuroiwa M; Nishi A
    Eur J Neurosci; 2008 May; 27(10):2551-7. PubMed ID: 18489579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
    Liu B; Dluzen DE
    Synapse; 2006 Oct; 60(5):354-61. PubMed ID: 16838362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New perspectives on the mechanism of methamphetamine-induced neurotoxicity].
    Kita T; Takeshima M; Wagner GC; Hozumi H; Miyazaki I; Asanuma M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):49-61. PubMed ID: 18516983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sex and temporally-dependent effects of methamphetamine toxicity on dopamine markers and signaling pathways.
    Bourque M; Dluzen DE; Di Paolo T
    Neuropharmacology; 2012 Jun; 62(7):2363-72. PubMed ID: 22369785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice.
    Iwashita A; Mihara K; Yamazaki S; Matsuura S; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1114-24. PubMed ID: 15113847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen.
    Mignini F; Tomassoni D; Traini E; Amenta F
    J Neuroimmunol; 2009 Jan; 206(1-2):5-13. PubMed ID: 19012970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
    Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
    Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice.
    Lewis C; Dluzen DE
    Neurosci Lett; 2008 Dec; 448(1):130-3. PubMed ID: 18852023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine.
    Chipana C; García-Ratés S; Camarasa J; Pubill D; Escubedo E
    Neurochem Int; 2008 Feb; 52(3):401-10. PubMed ID: 17716785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity.
    Thomas DM; Kuhn DM
    J Pharmacol Exp Ther; 2005 May; 313(2):870-6. PubMed ID: 15718289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
    Truong JG; Rau KS; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2003 Aug; 474(2-3):223-6. PubMed ID: 12921866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.